Design Therapeutics (DSGN) Cash from Operations (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Cash from Operations of 15524000.0 for Q2 2026, down 7.5% year-over-year from 16782608.47 in Q2 2025, and up 5.52% on a QoQ basis from 16431000.0 in Q1 2026.
Powered by 
Analysis
Design Therapeutics (DSGN) Cash from Operations (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 15524000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 15524000.0, down 7.5% year-over-year; the trailing twelve-month figure through Jun 2026 was 55083000.0 (down 8.78% YoY), and the FY2025 annual result was 54358000.0, down 26.11% from the prior year.
- Cash from Operations climbed to 15524000.0 in Q2 2026, from 16431000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 9546000.0 in Q3 2024 and troughed at 17424000.0 in Q1 2023.
- A 5-year average of 13294166.67 and a median of 13301000.0 in 2023 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2022, when Cash from Operations tumbled 219.91%; it then soared 34.32% in 2024.
- A 5-year view of Cash from Operations shows it stood at 15091000.0 in 2022, then rose by 15.19% to 12798000.0 in 2023, then grew by 22.96% to 9860000.0 in 2024, then decreased by 21.36% to 11966000.0 in 2025, then slipped by 29.73% to 15524000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 15524000.0 in Q2 2026, 16431000.0 in Q1 2026, and 11966000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - | -15.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.52 Mn |
| Mar 31, 2026 | -16.43 Mn |
| Dec 31, 2025 | -11.97 Mn |
| Sep 30, 2025 | -11.16 Mn |
| Jun 30, 2025 | -14.44 Mn |
| Mar 31, 2025 | -16.79 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -9.55 Mn |
| Jun 30, 2024 | -11.26 Mn |
| Mar 31, 2024 | -12.44 Mn |
| Dec 31, 2023 | -12.80 Mn |
| Sep 30, 2023 | -14.53 Mn |
| Jun 30, 2023 | -13.80 Mn |
| Mar 31, 2023 | -17.42 Mn |
| Dec 31, 2022 | -15.09 Mn |
| Sep 30, 2022 | -13.90 Mn |
| Jun 30, 2022 | -10.50 Mn |
| Mar 31, 2022 | -11.83 Mn |
| Dec 31, 2021 | -9.23 Mn |
| Sep 30, 2021 | -8.16 Mn |